TherapeuticsMD (TXMD) Provides Update on Third Quarter Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
TherapeuticsMD Provides Update on Third Quarter Progress
September 25, 2020 9:02 AM EDT-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA®-
-Underlying retail and wholesale demand for ANNOVERA is strong and growing-
-Company experiencing record retail and wholesale growth for ANNOVERA-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Companys ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen... More
